IPAC-RS seeks to advance the science of orally inhaled and nasal drug products (OINDP) by collecting and analyzing data, and conducting joint research and development projects. We aim to build consensus and contribute to effective regulations and standards by sharing the results of our research through conferences, technical journals, and discussions with regulatory bodies.
IPAC-RS represents the interests of its members to United States and international authorities and standard-setting bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Evaluation Agency (EMEA), the United States Pharmacopeia (USP), the International Conference on Harmonization (ICH), the International Organization for Standardization (ISO), and others.
The Consortium is governed by the Board of Directors, which is comprised of representatives from each member company. Technical work is carried out through working groups and technical committees established by the Board for specific initiatives. The IPAC-RS Secretariat provides project management, administrative and other assistance for all projects. By exploring our site, you will find further information about IPAC-RS’s current and future activities. |
Text Size (
